Tomás Ripoll-Vera1, José María Gámez2, Nancy Govea3, Yolanda Gómez2, Juana Núñez2, Lorenzo Socías2, Ángela Escandell2, Jorge Rosell3. 1. Servicio de Cardiología, Hospital Son Llàtzer, IdISPa, Ciberobn, Palma de Mallorca, Balearic Islands, Spain. Electronic address: tripoll@hsll.es. 2. Servicio de Cardiología, Hospital Son Llàtzer, IdISPa, Ciberobn, Palma de Mallorca, Balearic Islands, Spain. 3. Sección de Genética, Hospital Son Espases, Palma de Mallorca, Balearic Islands, Spain.
Abstract
INTRODUCTION AND AIMS: Mutations in the troponin T gene (TTNT2) have been associated in small studies with the development of hypertrophic cardiomyopathy characterized by a high risk of sudden death and mild hypertrophy. We describe the clinical course of patients carrying mutations in this gene. METHODS: We analyzed the clinical characteristics and prognosis of patients with mutations in the TNNT2 gene who were seen in an inherited cardiac disease unit. RESULTS: Of 180 families with genetically studied cardiomyopathies, 21 families (11.7%) were identified as having mutations in TNNT2: 10 families had Arg92Gln, 5 had Arg286His, 3 had Arg278Cys, 1 had Arg92Trp, 1 had Arg94His, and 1 had Ile221Thr. Thirty-three additional genetic carriers were identified through family assessment. The study included 54 genetic carriers: 56% were male, and the mean average age was 41 ± 17 years. There were 33 cases of hypertrophic cardiomyopathy, 9 of dilated cardiomyopathy, and 1 of noncompaction cardiomyopathy, and maximal myocardial thickness was 18.5 ± 6mm. Ventricular dysfunction was present in 30% of individuals and a history of sudden death in 62%. During follow-up, 4 patients died and 14 (33%) received a defibrillator (8 probands, 6 relatives). Mean survival was 54 years. Carriers of Arg92Gln had early disease development, high penetrance, a high risk of sudden death, a high rate of defibrillator implantation, and a high frequency of mixed phenotype. CONCLUSIONS: Mutations in the TNNT2 gene were more common in this series than in previous studies. The clinical and prognostic profiles depended on the mutation present. Carriers of the Arg92Gln mutation developed hypertrophic or dilated cardiomyopathy and had a significantly worse prognosis than those with other mutations in TNNT2 or other sarcomeric genes.
INTRODUCTION AND AIMS: Mutations in the troponin T gene (TTNT2) have been associated in small studies with the development of hypertrophic cardiomyopathy characterized by a high risk of sudden death and mild hypertrophy. We describe the clinical course of patients carrying mutations in this gene. METHODS: We analyzed the clinical characteristics and prognosis of patients with mutations in the TNNT2 gene who were seen in an inherited cardiac disease unit. RESULTS: Of 180 families with genetically studied cardiomyopathies, 21 families (11.7%) were identified as having mutations in TNNT2: 10 families had Arg92Gln, 5 had Arg286His, 3 had Arg278Cys, 1 had Arg92Trp, 1 had Arg94His, and 1 had Ile221Thr. Thirty-three additional genetic carriers were identified through family assessment. The study included 54 genetic carriers: 56% were male, and the mean average age was 41 ± 17 years. There were 33 cases of hypertrophic cardiomyopathy, 9 of dilated cardiomyopathy, and 1 of noncompaction cardiomyopathy, and maximal myocardial thickness was 18.5 ± 6mm. Ventricular dysfunction was present in 30% of individuals and a history of sudden death in 62%. During follow-up, 4 patientsdied and 14 (33%) received a defibrillator (8 probands, 6 relatives). Mean survival was 54 years. Carriers of Arg92Gln had early disease development, high penetrance, a high risk of sudden death, a high rate of defibrillator implantation, and a high frequency of mixed phenotype. CONCLUSIONS: Mutations in the TNNT2 gene were more common in this series than in previous studies. The clinical and prognostic profiles depended on the mutation present. Carriers of the Arg92Gln mutation developed hypertrophic or dilated cardiomyopathy and had a significantly worse prognosis than those with other mutations in TNNT2 or other sarcomeric genes.
Authors: M Alejandra Restrepo-Cordoba; Oscar Campuzano; Tomás Ripoll-Vera; Marta Cobo-Marcos; Irene Mademont-Soler; José M Gámez; Fernando Dominguez; Esther Gonzalez-Lopez; Laura Padron-Barthe; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Ramon Brugada; Pablo Garcia-Pavia Journal: J Cardiovasc Transl Res Date: 2017-01-30 Impact factor: 4.132
Authors: Jamie R Johnston; Maicon Landim-Vieira; Mayra A Marques; Guilherme A P de Oliveira; David Gonzalez-Martinez; Adolfo H Moraes; Huan He; Anwar Iqbal; Yael Wilnai; Einat Birk; Nili Zucker; Jerson L Silva; P Bryant Chase; Jose Renato Pinto Journal: J Biol Chem Date: 2019-11-20 Impact factor: 5.157